Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price rose 7.7% during trading on Thursday . The stock traded as high as C$2.12 and last traded at C$2.10. Approximately 87,902 shares were traded during trading, a decline of 29% from the average daily volume of 124,622 shares. The stock had previously closed at C$1.95.
Medicenna Therapeutics Stock Performance
The stock has a market cap of C$166.01 million, a P/E ratio of -9.65 and a beta of 1.29. The company’s 50-day simple moving average is C$2.13 and its 200 day simple moving average is C$1.62. The company has a current ratio of 5.00, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06.
About Medicenna Therapeutics
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 7/22 – 7/26
- Why Invest in High-Yield Dividend Stocks?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
